Inspired by a mission to help organizations like yours advance ophthalmic research, Emmes has contributed to the development of innovative therapeutic solutions impacting millions of people since 1977.
With specific experience in age-related macular degeneration (AMD), diabetic retinopathy, and several rare eye diseases, our team of experienced clinical research professionals is here to support your research and help improve the treatment landscape for ophthalmology patients.
Clinical Research Experience
With an aging population and the flurry of new treatment options for people suffering from ophthalmic diseases, the past ten years have been an exciting time for Emmes and its clients. Through our long-standing relationship with the National Eye Institute, we’ve contributed to major breakthroughs in age-related macular degeneration and pediatric rare diseases worldwide.
Many of those breakthroughs result from advances in cell and gene therapy, a key area of specialization for Emmes. Through our core competency in cell and gene therapy, Emmes provides you with unique perspectives and expert insights into the latest research in AMD. From our work on the AREDS and AREDS 2 trials, to the gene therapy and stem cell studies we conduct today, Emmes has supported clients at the forefront of AMD science. As a result of our collaborations, AREDS products are available to patients at risk for Advanced AMD.
Emmes has also collaborated in the ongoing quest to develop methods for early diagnosis of diabetic retinopathy. We were proud to have supported the research efforts behind IDx-DR, which became the first FDA approved AI-based diagnostic system. The IDx-DR autonomously analyzes images of the retina for signs of diabetic retinopathy — a disease that blinds 24,000 people each year.
Biostatistics and Bioinformatics
Since our founding in 1977 by a biostatistician, Emmes has been known as a “statistics-driven” CRO. We make it a point to involve biostatisticians across the clinical trial journey because we realize the value of high quality data to our clients.
Ophthalmic studies present novel statistical challenges that often require analysis of correlated outcomes or estimating treatment effects for bilateral or unilateral diseases. Emmes biostatisticians have developed robust novel analytical approaches for studies in rare ophthalmic diseases and have expertise analyzing visual outcomes.
If your ophthalmology study requires sophisticated analysis of genomic, proteomic, transcriptomic, metabolomic and other “omics” data analysis, you may wish to employ Emmes’ bioinformatics experts who can deliver a variety of solutions for you, including machine learning, advanced data visualization, pathways analysis, scalable cloud computing and reproducible data analysis methods.
Specialty Ophthalmic Products and Services
In addition to helping you with clinical research services, Emmes provides two services to support site personnel and make your research a success.
- Emmes Optym provides training and certification of clinical center staff to ensure reliable acquisition of high quality visual acuity outcomes data in clinical trials.
- Emmes EVA provides Electronic Visual Acuity (EVA) devices designed to replace traditional eye charts and manually-proctored visual acuity protocols. The result is reduced chance of human testing error, higher quality data and better structured reporting.
Our history and proven outcomes working with multiple ophthalmic disease states, patient populations and recruitment strategies provide an optimal package for supporting your ophthalmology clinical research.Contact Us
At Emmes, we value the open exchange of communication between our therapeutic area leaders and your team. We encourage you to contact us to discuss your research plan and determine how we can support your development pathway.